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Abstract
Introduction: The present study examined the effect of collagen fragments on anabolic and catabolic activities by 
chondrocyte/agarose constructs subjected to dynamic compression.
Methods: Constructs were cultured under free-swelling conditions or subjected to continuous and intermittent 
compression regimes, in the presence of the N-terminal (NT) and C-terminal (CT) telopeptides derived from collagen 
type II and/or 1400 W (inhibits inducible nitric oxide synthase (iNOS)). The anabolic and catabolic activities were 
compared to the amino-terminal fibronectin fragment (NH2-FN-f) and assessed as follows: nitric oxide (NO) release and 
sulphated glycosaminoglycan (sGAG) content were quantified using biochemical assays. Tumour necrosis factor-α 
(TNFα) and interleukin-1β (IL-1β) release were measured by ELISA. Gene expression of matrix metalloproteinase-3 
(MMP-3), matrix metalloproteinase-13 (MMP-13), collagen type II and fibronectin were assessed by real-time 
quantitative polymerase chain reaction (qPCR). Two-way ANOVA and the post hoc Bonferroni-corrected t-test was used 
to examine data.
Results: The presence of the NT or CT peptides caused a moderate to strong dose-dependent stimulation of NO, TNFα 
and IL-1β production and inhibition of sGAG content. In some instances, high concentrations of telopeptides were just 
as potent in stimulating catabolic activities when compared to NH2-FN-f. Depending on the concentration and type of 
fragment, the increased levels of NO and cytokines were inhibited with 1400 W, resulting in the restoration of sGAG 
content. Depending on the duration and type of compression regime employed, stimulation with compression or 
incubation with 1400 W or a combination of both, inhibited telopeptide or NH2-FN-f induced NO release and cytokine 
production and enhanced sGAG content. All fragments induced MMP-3 and MMP-13 expression in a time-dependent 
manner. This effect was reversed with compression and/or 1400 W resulting in the restoration of sGAG content and 
induction of collagen type II and fibronectin expression.
Conclusions: Collagen fragments containing the N- and C-terminal telopeptides have dose-dependent catabolic 
activities similar to fibronectin fragments and increase the production of NO, cytokines and MMPs. Catabolic activities 
were downregulated by dynamic compression or by the presence of the iNOS inhibitor, linking reparative activities by 
both types of stimuli. Future investigations which examine the signalling cascades of chondrocytes in response to 
matrix fragments with mechanical influences may provide useful information for early osteoarthritis treatments.
Introduction
The ability of degradation products of the extracellular
matrix to regulate cartilage homeostasis and influence
osteoarthritis (OA) disease progression has been exten-
sively studied [1,2]. For instance, different types of matrix
fragments derived from fibronectin or collagen can signal
and amplify catabolic processes in chondrocytes that act
to either remove tissue components for repair or to initi-
ate reparative signals [3,4]. Chondrocytes will addition-
ally respond to biomechanical perturbation such that
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mechanical loading on normal or diseased tissue will
c o n t r i b u t e  t o  s i g n a l l i n g  c a s c a d e s  a n d  u p r e g u l a t e  s y n -
t h e t i c  a c t i v i t y  o r  i n c r e a s e  t h e  l e v e l s  o f  i n f l a m m a t o r y
mediators [5-7]. Our understanding of what factors initi-
ate the early phase of matrix damage in OA is poor. The
question of whether mechanical loading modulates
matrix fragment induced mechanisms for repair and/or
degradation in early stage OA is not known.
The inflammatory pathways induced by fibronectin
fragments (FN-fs) in chondrocytes are well characterised
[8,9]. For instance, the amino-terminal fibronectin frag-
ment (NH2-FN-f) has potent catabolic activities and was
shown to increase cytokines (interleukin-1α (IL-1α),
interleukin-1β (IL-1β), tumour necrosis factor-α (TNFα),
interleukin-6 (IL-6)), matrix metalloproteinases (matrix
metalloproteinase-3 (MMP-3), matrix metalloproteinase-
13 (MMP-13)) and nitric oxide (NO) production in
human and bovine cartilage [10-14]. The signalling path-
ways involve the mitogen activated protein kinase
(MAPK) and nuclear factor-kappa B (NFκ B) cascades
mediated by stimulation of integrin receptors, leading to
a suppression of proteoglycan synthesis and increased
proteoglycan depletion in chondrocytes [15-19]. In addi-
tion, the N-terminal (NT) telopeptide from collagen type
II was shown to upregulate MMP-3 and MMP-13 levels
in human and bovine cartilage [20-22]. However, collagen
fragments (Col-fs) containing the NT or C-terminal (CT)
telopeptide regions were much slower at increasing MMP
levels when compared to the NH2-FN-f [23]. This differ-
ence could be reflected in the differential rate of activa-
tion of members of the MAPK or NFκB family, leading to
the production of common catabolic mediators such as
NO [19]. Recently, we showed that compressive loading
inhibits NH2-FN-f induced NO production and restores
m a t r i x  s y n t h e s i s  i n  c h o n d r o c y t e s  c u l t u r e d  i n  a g a r o s e
constructs [24]. It is plausible that mechanical loading
competes with the catabolic pathways induced by the
matrix fragments and contributes to early reparative sig-
nals in chondrocytes. The present study therefore com-
pared the effect of Col-fs with the NH2-FN-f on the
production of NO, cytokines and MMPs in chondrocyte/
agarose constructs subjected to dynamic compression.
Materials and methods
Chondrocyte isolation and culture in agarose constructs
Articular cartilage was harvested from the porcine meta-
carpalphalangeal joints of freshly slaughtered 12-month-
old pigs from a local abattoir (FEL GmbH, Leipzig, Ger-
many). Cartilage tissue was pooled from six joints, diced
and incubated on rollers for one hour at 37°C in Dul-
becco's Modified Eagle's Medium (DMEM) supple-
mented with 10% (v/v) foetal calf serum (FCS) + 2 μ M L-
glutamine, 5 μ g.ml-1 penicillin, 5 μ g.ml-1 streptomycin,
20 mM Hepes buffer, and 0.05 mg/ml L-ascorbic acid +
700 unit.ml-1 pronase, and incubated for a further 16
hours at 37°C in DMEM + 10% FCS (all from Sigma-
Aldrich, Taufkirchen, Germany) supplemented with 2
mg.ml-1 collagenase A (Biochrom KG, Berlin, Germany).
The cell suspension was washed and viable chondrocytes
counted using a haemocytometer and trypan blue. Cells
were finally resuspended in medium at a cell concentra-
tion of 8 × 106  cells.ml-1  using established methods
[25,26]. Briefly, the cell suspension was added to an equal
volume of molten 6% (w/v) agarose type VII in Earle's
Balanced Salt Solutions (EBSS) to yield a final cell con-
centration of 4 × 106  cells.ml-1  in 3% (w/v) agarose
(Sigma-Aldrich, Taufkirchen, Germany). The chondro-
cyte/agarose suspension was transferred into a sterile
stainless steel mould, containing holes 10 mm in diame-
ter and 3 mm in height and allowed to gel at 4°C for 20
minutes to yield cylindrical constructs. All constructs
were maintained in culture in 1 ml of DMEM + 10% FCS
at 37°C in 5% CO2 for 24 hours.
Dose-response effect of telopeptides in chondrocyte/
agarose constructs
The dose-response effect of the N-terminal (NT) and C-
terminal (CT) telopeptides derived from collagen type II
were examined in constructs cultured under free-swell-
ing conditions for 48 hours. The synthetic peptides were
less than 10 kDa in size and were synthesised by Sigma
Genosys (Haverhill, UK), using sequences published pre-
viously [20-23]. More specifically, the NT peptide corre-
sponds to the amino-terminal region of collagen type II
and contains 19 amino acids (residues 182 to 212) with an
additional four glycine-proline-hydroxyproline (GPX) tri-
peptide repeat resulting in a short 31-mer peptide
(sequence: QMAGGFDEKAGGAGLGVMQGPMGP-
MGPRGPP). The CT peptide corresponds to the car-
boxyl-terminal end of collagen type II and contains 24
amino acids (residues 1218 to 1241; sequence: IDMSAF-
AGLGPREKGPDPLQYMRA). The constructs were cul-
tured in 1 ml of DMEM + 1 × ITS liquid media (Sigma-
Aldrich, Taufkirchen, Germany) supplemented with
either 0, 0.05, 0.5, 5 and 50 μM NT or 0.05, 0.5, 5 and 50
μM CT peptide in the presence and absence of 1 mM N-
(3-(aminomethyl) benzyl)acetamidine.2HCL (1400 W)
(Merck Biosciences, Nottingham, UK). 1400 W is a
chemical inhibitor which specifically inhibits the induc-
ible nitric oxide synthase (iNOS) enzyme. An optimal
concentration of the scrambled form of the NT (SN (19
residues; sequence: GPGAGQPGKGRGPAPLQFG-
MAMMDMADPGEV)) and CT (SC (24 residues;
sequence: MARFPAMLGPARDPISYQKEGDGL)) pep-
tides were used as negative controls (both at 50 μM). A
commercially available 30 kDa NH2-FN-f at 1 μM was
used as a positive control (Sigma-Aldrich, Poole, UK). AtChowdhury et al. Arthritis Research & Therapy 2010, 12:R82
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the end of the culture period, the constructs and corre-
sponding media were immediately stored at -20°C prior
to biochemical analysis.
Application of dynamic compression
The present study utilized a bioreactor device (Ingenieur-
buro, GmbH, Braunschweig, Germany) to apply com-
pressive loading to chondrocyte/agarose constructs,
using a system described previously [27]. Briefly, the bio-
reactor vessel consists of two chambers with a cylindrical
lid that fits a magnetic actuator connected to a stainless
steel loading plate (Figure 1a). Six constructs were held
under confined conditions in a locating stage with an
inner and outer wall (Figure 1a, inset). This arrangement
limits axial movement of the loading plate therefore
allowing the system to apply a known compressive strain.
Both the locating stage and loading plate were fluid per-
meable (TECAPEEK, Ensinger GmbH and Co., Nufrin-
gen, Germany) and perforated to facilitate nutrient
transport to all surfaces of the construct. The lower
chamber has two ports enabling media and gas exchange
while the upper chamber fits two connectors for pH and
O2 biosensors. Culture media containing either 50 μM
NT or 50 μM CT or 1 μM NH2-FN-f and/or 1 mM 1400
W were introduced to the lower chamber. The vertical
motion of the magnetic actuator and loading plate was
controlled by a magnet field induced by an external Tesla
NdFeB magnet which rotated above the bioreactor. Vari-
ous continuous and intermittent compression regimes
were employed over a 6 or 48 hour culture period result-
ing in a total number of compression cycles which ranged
from 4800 to 172800 (Figure 1b). The following periods
of compression were applied to constructs in a dynamic
manner at 15% strain and a frequency of 1 Hz: 10 minutes
compression with a 5 hour 50 minutes unstrained period
(10 minutes/5 hr 50×1); 1.5 hour compression with a 4.5
hour unstrained period (1.5 hr/4.5 hr×1); 6 hours of con-
tinuous compression (C6); 10 minutes compression with
a 5 hour 50 minute unstrained period repeated 8 × (10
minutes/5 hr 50×8); 1.5 hour compression with a 4.5 hour
unstrained period repeated 8 × (1.5 hr/4.5 hr×8) and 48
hours of continuous compression (C48). Dynamic com-
pression was applied with a load and displacement con-
trol feedback system. A typical response for the load and
displacement profile generated with a sinusoidal wave-
form is illustrated in Figure 1c. This ensured a maximum
load of 12 N which remained constant during the 48 hour
compression period. The displacement curves showed
similar profiles at time = 0, 1 and 48 hours and was equiv-
alent to a deformation of 450 μM and displacement of
15% strain. For control constructs, the fluid permeable
loading plate was situated 0.8 mm above the construct to
facilitate nutrient transport and cultured in an unstrained
state at 0% strain for the same time period within the bio-
reactor device. At the end of the culture period, all con-
structs and corresponding media were immediately
stored at -80°C prior to analysis.
RNA isolation, cDNA synthesis and real-time quantitative 
polymerase chain reaction (qPCR)
RNA was isolated from chondrocytes cultured in agarose
using protocols described in the QIAquick®  Spin gel
extraction and RNeasy®  kits, as previously described
[24,28]. (Qiagen, Hilden, Germany). Following the manu-
facturer's instructions, Ambion's DNA-free DNase treat-
ment and removal reagents were used to eliminate any
contaminating DNA from the RNA sample (Ambion,
Applied Biosystems, Warrington, UK). RNA was quanti-
fied on the Nanodrop ND-1000 spectrophotometer
(LabTech, East Sussex, UK) and reverse transcription per-
formed using manufacturer's protocols from the M-MLV
First-Strand cDNA synthesis kit, oligo(dT)15 primer and a
total of 200 ng of RNA (Promega, Manheim, Germany).
For real-time quantitative PCR, the cDNA was amplified
in 25 μl reaction mixtures containing 1 μl cDNA, 12.5 μl
SYBR® Green PCR Master Mix, primer pairs (Table 1) and
nuclease free PCR grade water (Applied Biosystems)
using an automated PCR robot (CAS-1200™, Corbett
Research, Cambridge, UK). Each sample was run in
duplicate on the 72-well thermal system of the Rotor-
Gene™ 3000 instrument (Corbett Research). Thermocy-
cling conditions comprised of an initial polymerase acti-
vation step at 95°C for 3 minutes, followed by 35 cycles at
95°C for 30 s, at 55°C for 60 s and at 72°C for 60 s. Follow-
ing amplification, a melt curve was obtained to ensure no
detection of primer-dimers and non-specific products. In
order to screen for contamination of reagents or false
amplification, PCR controls were prepared for each sam-
ple by preparing identical reaction mixtures except for
the addition of the template (NTC). No reverse tran-
scriptase (NoRT) controls were additionally included in
each PCR assay.
Fluorescence data were collected during the annealing
stage of amplification and data were analysed using the
RG-3000™ qPCR software (version 6, Corbett Research).
Baselines and thresholds were automatically set by the
RG-3000™ qPCR software and used after manual inspec-
tion. The cycle threshold (Ct) value for each duplicate
reaction was expressed as the mean value and the results
were exported into Microsoft Excel for further analysis.
The data obtained by PCR assay for Glyceraldehyde-3-
Phosphate Dehydrogenase (GAPDH) were validated as a
reference gene by displaying the Ct values as Box and
Whisker plots and the distribution examined under
mechanical loading conditions (data not shown). The Ct
v a l u e s  f o r  G A P D H  r e m a i n e d  s t a b l e  w i t h  n o  c h a n g e s
detected under all treatment conditions, suggesting itsChowdhury et al. Arthritis Research & Therapy 2010, 12:R82
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Figure 1 Schematic illustrating components of the bioreactor device and experimental compression regimes. (a) Six chondrocyte/agarose 
constructs were held under confined conditions in a locating stage as shown in the inset. Both the locating stage and loading plate were fluid per-
meable and perforated to facilitate nutrient transport to all surfaces of the construct. (b) The compression regimes are shown in the middle panel 
resulting in a total number of cycles ranging from 600 to 172,800 over a 6- or 48-hour culture period. Black bars indicate unstrained periods equivalent 
to 0% strain. (c) Black lines show typical response profiles for load and displacement generated with a sinusoidal waveform at time = 0 (dash), 1 (dash 
dot) and 48 hours (square dot), respectively.
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suitability as a reference gene. Relative quantification of
MMP-3, MMP-13, collagen type II and fibronectin sig-
nals was accomplished by normalizing each target to the
reference gene, GAPDH and to the calibrator sample
(unstrained, untreated sample) by a comparative Ct
approach [29]. For each sample, the ratio of target ΔCt
and reference ΔCt was calculated, as shown in equation 1.
Where: E represents the efficiencies obtained for the
target and reference gene. ΔCttarget represents the differ-
ence in Ct values for the mean calibrator or sample for the
target gene. ΔCtReference represents the difference in Ct
values for the mean calibrator or sample for the reference
gene, GAPDH.
PCR efficiencies for primer pairs with SYBR green were
derived from standard curves (n = 3) by preparing a 10-
fold serial dilution of cDNA from a sample which repre-
sents the untreated sample. The real-time PCR efficien-
cies (E) of amplification for each target was defined
according to the relationship, E = 10 [-1/slope]. The R2
value of the standard curve exceeded 0.9998 and revealed
efficiency values presented in Table 1.
Biochemical analysis
At the end of the experiment, constructs were digested in
phosphate buffered saline (PBS) supplemented with 10
mM L-cysteine and 10 mM EDTA, pH 6.5 for 60 minutes
at 70°C and subsequently incubated with 1.66 Units/mL
agarase for 16 hours at 37°C and with 0.1 units/mL
Papain for 1 hour at 60°C, as previously described [25,26].
DNA levels were determined in the agarase/papain
digests by Quant-iT™ PicoGreen® dsDNA assay according
to manufacturer's instructions (Molecular Probes,
Eugene, OR, USA). Sulphated glycosaminoglycan (sGAG)
content was determined using the 1, 9-dimethyl-methyl-
ene blue dye-binding assay in agarose/papain digests and
media samples and the values normalized to DNA levels
[25,26]. The production of NO was determined in media
by converting nitrate to nitrite using 1 unit.ml-1 nitrate
reductase in 40 μM NAPDH, 500 μM glucose 6-phos-
phate, 160 unit.ml-1 glucose 6-phosphate dehydrogenase
and 20 mM Tris-HCL for 15 minutes at 37°C and total
nitrite assayed spectrophotometrically at 540 nm using
the Griess reaction, as described previously [30,31]. The
levels of IL-1β and TNFα were determined in media sam-
ples by commercial ELISA kits according to manufac-
turer's instructions (R & D Systems Europe Ltd,
Abingdon, UK).
Table 1: Description of the sequences used to quantify gene expression and real-time reaction efficiencies of PCR assays
Gene Gene ID Sequences Product size (bp) Efficiency
MMP-3
396769 Forward: 5'-ACCCAAGAAGTATCCACACCCT-3' 215 1.98 ± 0.06
Reverse: 5'-TGCTTCAAAGACAGCATCCACT-3'
MMP-13
397346 Forward: 5'-CCAAAGGCTACAACTTGTTTCTTG-3' 77 1.99 ± 0.03
Reverse: 5'-TGGGTCCTTGGAGTGGTCAA-3'
Collagen type II
397323 Forward: 5'-CGCTGAACATCCTCACAAC-3' 249 1.98 ± 0.19
Reverse: 5'-TCCTGTAGATACGCCTAAGC-3'
Fibronectin
397620 Forward: 5'-GACAGATGAGCTTCCCCAAC-3' 752 2.02 ± 0.09
Reverse: 5'-CACTGCCAAAGCCTAAGCAC-3'
GAPDH
396823 Forward: 5'-AATCCCATCACCATCTTCCA-3' 318 2.03 ± 0.01
Reverse: 5'-TGTGGTCATGAGTCCTTCCA-3'
Primers used in quantitative polymerase chain reaction (qPCR) experiments with SYBR green produced amplicons of 77 to 752 base pairs with 
efficiency values between 1.98 and 2.03. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; MMP-3, matrix metalloproteinase-3; MMP-13, 
matrix metalloproteinase-13.
Ratio = 
(1 + ETarget)  Target (MEAN Calibrator – Sample) 
(1 + EReference) 
 Ct
Reference (MEAN Calibrator – Sample) 
 CtChowdhury et al. Arthritis Research & Therapy 2010, 12:R82
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Statistics
For the dose-response studies, data represent the mean
and standard error of the mean (SEM) values of six repli-
cates from two separate experiments. For the mechanical
loading experiments, data represent the mean and SEM
values of eight replicates from two separate experiments.
Statistical analysis was performed by a two-way analysis
of variance (ANOVA) and the multiple post hoc Bonfer-
roni-corrected  t-tests to compare differences between
treatment groups as indicated in the figure legend. In all
cases, a level of 5% was considered statistically significant
(P < 0.05).
Results
Telopeptides increase NO production and inhibit sGAG 
content in a dose-dependent manner
The ability of NT and CT peptides to influence NO
release and sGAG content in constructs cultured for 48
hours are illustrated in Figure 2. The levels of NO were
enhanced by the presence of the NT or CT peptides, with
significant levels at 0.5 μM and increasing up to 50 μM
when compared to untreated controls (P < 0.001 and P <
0.05; Figure 2a and 2b, respectively). This effect was simi-
lar to treatment with NH2-FN-f and showed significant
l ev e l s  o f  NO  p r o d u c t i o n  w h e n  c o m p a r e d  t o  u n t r e a t e d
controls (P < 0.001). At 50 μM, co-incubation with 1400
W inhibited telopeptide or FN-f-induced NO release with
levels returning to basal values. In contrast, the presence
of the NT or CT peptides did not influence sGAG con-
tent at a concentration ranging from 0.05 to 5 μM when
compared to untreated controls (Figure 2c, d). At 50 μM,
the presence of the NT or CT peptides partially inhibited
sGAG content (P < 0.01) and this effect was reversed with
1400 W for the NT peptide, only (P < 0.05; Figure 2c).
The NH2-FN-f strongly inhibited sGAG content (P  <
0.001) and the response was reversed with 1400 W (P <
0.001). The control SN or SC peptides did not signifi-
cantly influence NO production and sGAG content in the
presence and absence of 1400 W.
Telopeptides increase cytokine levels in a dose-dependent 
manner
We next characterised the dose-response effect of NT
and CT peptides on the production of IL-1β and TNFα in
constructs cultured for 48 hours (Figure 3). The presence
of the NT or CT peptides enhanced TNFα release when
compared to untreated controls, with significant levels at
5 (P < 0.05) and 50 μM (P < 0.001) for the NT peptide and
at 0.05 (P < 0.05), 5 (P < 0.05) and 50 μM (P < 0.001) for
the CT peptide (Figure 3a and 3b, respectively). At 50
μM, peptide-induced TNF-α release was inhibited with
1400W (P < 0.001; Figure 3a, b). The presence of the NT
or CT peptides increased IL-1β production in a concen-
tration-dependent manner (Figure 3c and 3d, respec-
tively). This effect was inhibited with 1400 W resulting in
a significant reduction at 50 μM NT (P < 0.001) or with 5
and 50 μM CT peptide (both P < 0.05). The presence of
the NH2-FN-f increased maximal levels of TNFα and IL-
1β production when compared to untreated controls and
this effect was inhibited with 1400 W (P < 0.001). The
control SN and SC peptides did not influence cytokine
levels in the presence and absence of 1400 W.
Dynamic compression modulates telopeptide induced NO 
release and restores sGAG content
Having demonstrated that treatment with NT or CT pep-
tides influenced NO release and sGAG production in a
concentration-dependent manner, subsequent studies
examined the effect of continuous or intermittent com-
pression on the peptide or NH2-FN-f induced response
(Figure 4). Under no treatment conditions, no significant
differences were detected for NO release in unstrained
constructs and constructs subjected to compression for
10 minutes/5 hr 50×8, 1.5 hr/4.5 hr×8 or C48 hours (Figure
4a). In unstrained constructs, the presence of the NT or
CT peptides enhanced NO levels when compared to con-
structs cultured without the peptide (both P  < 0.001).
Stimulation with compression for 10 minutes/5 hr 50×8,
1.5 hr/4.5 hr×8 or C48 hours (all P < 0.01), or incubation
with 1400 W inhibited NO release (P < 0.001). This effect
could be further downregulated by co-stimulation with
both compression for C48 hours and 1400 W in peptide
treated constructs (P < 0.01). In unstrained constructs,
the NH2-FN-f increased maximal levels of NO release
when compared to untreated controls (P < 0.001). This
effect was inhibited under all compression regimes or
culture with the iNOS inhibitor (all P < 0.001). Co-stimu-
lation with both compression for 1.5 hr/4.5 hr×8 or C48
hours and 1400 W abolished FN-f-induced NO release
with values returning to basal levels (both P < 0.01).
Under no treatment conditions, sGAG content was
enhanced following stimulation with intermittent com-
pression for 1.5 hr/4.5 hr 50×8 or with continuous com-
pression for C48 hours (both P < 0.001; Figure 4b). In
unstrained constructs, the presence of the NT or CT pep-
tides inhibited sGAG content (both P < 0.05) and this
effect was partially reversed with compression for 1.5 hr/
4.5 hr×8 or C48 hours and/or 1400 W. In unstrained con-
structs, the NH2-FN-f inhibited sGAG content when
compared to untreated constructs (P < 0.001). This effect
was reversed with compression for 1.5 hr/4.5 hr×8 or C48
hours and/or culture with the iNOS inhibitor (all P  <
0.001). We did not detect significant changes in NO
release and sGAG content in constructs cultured with the
control SN or SC peptides and/or 1400 W.Chowdhury et al. Arthritis Research & Therapy 2010, 12:R82
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Dynamic compression inhibits telopeptide induced 
cytokine levels
Figure 5 examined the effect of continuous and intermit-
tent compression on cytokine production in the presence
and absence of telopeptides or NH2-FN-f for 48 hours.
Under no treatment conditions, the levels of TNFα or IL-
1β were not significantly influenced by compression for
10 minutes/5 hr 50×8, 1.5 hr/4.5 hr×8 or C48 hours. In
unstrained constructs, the presence of NT or CT pep-
tides increased TNFα and IL-1β production (both P <
0.001). This response was broadly inhibited under all
compression regimes and/or culture with 1400 W. In
unstrained constructs, the presence of the NH2-FN-f
increased TNFα or IL-1β release. This effect was inhib-
ited under all compression regimes and/or 1400 W. We
did not detect any significant changes in cytokine levels
for constructs cultured with the control SN and SC pep-
tides.
Dynamic compression modulates telopeptide induced 
gene expression
To investigate the temporal expression profile of catabolic
(MMP-3, MMP-13; Figure 6) and anabolic genes (colla-
gen type II, fibronectin; Figure 7), constructs were sub-
jected to continuous and intermittent compression in the
presence and absence of the NT and CT peptides or
NH2-FN-f for 6 or 48 hours. At six hours, the C6 regime
maximally increased MMP-3 expression when compared
t o  u n s t r a i n e d  c o n s t r u c t s  ( P  < 0.05; Figure 6a). At 48
hours, compression for 1.5 hr/4.5 hr×8  was the only
regime which increased MMP-3 expression (P < 0.05; Fig-
ure 6b). In unstrained constructs, treatment with telo-
peptides or NH2-FN-f for 6 or 48 hours increased MMP-3
Figure 2 Dose-response effect of NT and CT telopeptides. Constructs were cultured with NT (0.05 to 50 μM) or CT (0.05 to 50 μM) peptides under 
free-swelling conditions in the presence or absence of 1 mM 1400 W for 48 hours: (a) NO release and (b) sGAG content (n = 6). A scrambled form of 
the NT (SN) and CT (SC) peptide were used as negative controls (both at 50 μM). An NH2-FN-f (1 μM) was used as a positive control. (*) indicates sig-
nificant comparisons for 0 vs fragment; (+) indicates significant comparisons for fragment vs fragment + 1400 W (n = 6 ±).
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expression (all P < 0.001; Figure 6a and 6b, respectively).
This effect was inhibited under all compression regimes
and/or culture with the iNOS inhibitor. Under no treat-
ment conditions, compression for C6 or C48 hours did
not significantly influence MMP-13 expression (Figure
6c, d). In unstrained constructs, the presence of the telo-
peptides or NH2-FN-f increased MMP-13 at 6 hours (all
P < 0.01; Figure 6c) with maximal stimulation at 48 hours
(all P < 0.001; Figure 6d). This effect was inhibited under
all compression regimes and/or 1400 W at 6 or 48 hours.
The control SN and SC peptides did not significantly
influence MMP-3 or MMP-13 expression in constructs
subjected to dynamic compression.
Under no treatment conditions, compression for 10
minutes/5 hr 50×1, 1.5 hr/4.5 hr×1 or C6 hours increased
collagen type II and fibronectin expression (Figure 7a and
7c, respectively). In unstrained constructs, telopeptides
or NH2-FN-f decreased collagen type II and fibronectin
expression at six hours (both P < 0.001; Figure 7a, c). This
effect was partially reversed under all compression
regimes and/or 1400 W for peptide or fragment treated
constructs. At specific compression regimes, the iNOS
inhibitor increased fibronectin expression in the presence
of the NT peptide and FN-f at 48 hours (Figure 7d). We
did not detect any significant changes in collagen type II
or fibronectin expression under all test conditions at 48
hours (Figure 7b and 7d, respectively). The only excep-
tion was with the NH2-FN-f which increased fibronectin
expression in unstrained constructs and was partially
reversed by all compression regimes (Figure 7d).
Figure 3 Dose-response effect of NT and CT telopeptides. Constructs were cultured with NT (0.05 to 50 μM) or CT (0.05 to 50 μM) peptides under 
free-swelling conditions in the presence or absence of 1 mM 1400 W for 48 hours: (a) TNFα release and (b) IL-1β (n = 6). A scrambled form of the NT 
(SN) and CT (SC) peptide were used as negative controls (both at 50 μM). An NH2-FN-f (1 μM) was used as a positive control. (*) indicates significant 
comparisons for 0 vs fragment; (+) indicates significant comparisons for fragment vs fragment + 1400 W (n = 6).
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Discussion
OA is a complex disease and involves both biochemical
and mechanical factors which influence disease progres-
sion. The primary causative factors are due to an increase
in the levels of inflammatory mediators which contribute
to an imbalance between anabolic and catabolic signal-
ling processes. There is evidence demonstrating that the
enhanced levels of FN-fs and Col-fs will initiate matrix
destruction and accelerate production of catabolic medi-
ators [1-3,32-36]. Despite advances in our understanding
of the role of matrix fragments in cartilage biology, few
research groups have examined whether mechanical sig-
Figure 4 Effect of NT and CT telopeptides and dynamic compression (15%, 1 Hz) on NO release (a) and sGAG content (b). Unstrained and 
strained constructs were cultured with 50 μM NT or CT peptide and/or 1 mM 1400 W for 48 hours (n = 8). SN and SC peptides (50 μM) were used as 
negative controls. NH2-FN-f (1 μM) was used as a positive control. (*) indicates significant comparisons in unstrained constructs for no treatment vs 
fragment; (ψ) indicates significant comparisons in unstrained constructs for fragment vs fragment + 1400 W; + P < 0.05, ++ P < 0.01, +++ P < 0.001 
indicates significant comparisons between treatment conditions as shown (n = 6).
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nals could interfere with the fragment-induced pathways
and modulate cell function through a positive feedback
loop. In addition, pharmacological treatments have
attempted to manipulate the inflammatory pathways dur-
ing late stage OA [37,38]. Efforts have been largely disap-
pointing due to lack of studies identifying the molecular/
mechanical signals which control matrix repair and/or
degradation in early disease states. Our understanding of
the early mechanopathophysiology is poor, particularly in
terms of reliable biomarkers. Thus, studies which investi-
Figure 5 Effect of NT and CT telopeptides and dynamic compression (15%, 1 Hz) on cytokine production. Unstrained and strained constructs 
were cultured with NT or CT peptide (both 50 μM) and/or 1400 W (1 mM) for 48 hours: (a) TNFα release and (b) IL-1β release (n = 8). SN and SC peptides 
(50 μM) were used as negative controls. NH2-FN-f (1 μM) was used as a positive control. (*) indicates significant comparisons in unstrained constructs 
for no treatment vs fragment; (ψ) indicates significant comparisons in unstrained constructs for fragment vs fragment + 1400 W; + P < 0.05, ++ P < 
0.01, +++ P < 0.001 indicates significant comparisons between treatment conditions as shown (n = 8).
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gate factors for early treatments and preserve the biome-
chanical function of the joint are both worthwhile and
necessary.
The present study characterised the effect of Col-fs
containing the NT or CT telopeptide regions on catabolic
and anabolic activities and compared the response to the
NH2-FN-f utilising the chondrocyte/agarose model. In
dose-response studies, 48 hours of treatment with the NT
or CT peptides increased NO production, enhanced IL-
1β and TNFα production and inhibited sGAG content in
a concentration-dependent manner. Gene expression of
MMP-3 and MMP-13 was detected at 6 hours with maxi-
mal induction at 48 hours in unstrained constructs
treated with telopeptides or the NH2-FN-f. We provide
evidence that in some instances, a high concentration of
NT or CT peptide (50 μM) was just as effective in stimu-
lating catabolic activities as the NH2-FN-f (1 μM). The
concentrations used in the present study are comparable
to previous work which reported fragments encompass-
ing the amino-terminal 29 kDa FN-f vary in concentra-
tion between 0.1 and 1 μM in human OA synovial fluids
and NT and CT peptides were found to be 3 μm in a rab-
bit OA model [16,39-41]. We used a telopeptide concen-
tration which represents a diseased state, so it is highly
likely we are seeing maximum catabolic effects by the
Col-fs. In addition, the iNOS inhibitor blocked fragment-
induced catabolic activities and stimulated sGAG con-
tent. Col-fs may therefore serve to increase catabolic
activities through common pathways involving NO which
results in the subsequent production of MMPs and
cytokines. Our findings are supported by previous studies
which demonstrate the induction of MMPs and cytokines
in chondrocyte monolayers and cartilage explants cul-
tured with collagen derived peptides [20-23]. Further-
more, human chondrocytes treated with type II collagen
caused sequential induction of MMPs (MMP-1, 3, 13 and
14) and cytokine production (IL-1β, IL-6, IL-8) followed
by release of Col-fs from mature collagen fibres [42]. The
catabolic process involved activation of p38 MAPK and
NFκB leading to the production of MMPs and cytokines
[42]. Overproduction of the matrix degrading enzymes
will additionally release telopeptides from the triple helix,
generating further Col-fs [43]. In OA, the enhanced
action of MMPs on matrix proteins will generate several
types of fragments released through different enzymatic
pathways. It is plausible that fragments from collagen or
fibronectin may arise from the degenerating matrix and
promote a catabolic state through activation of common
pathways. This is turn generates more matrix fragments
which amplifies MMPs in a positive feedback loop [9,12].
Figure 6 Effect of NT and CT telopeptides and dynamic compression (15%, 1 Hz) on gene expression. Unstrained and strained constructs were 
cultured with either NT or CT peptide (both 50 μM) and/or 1400 W (1 mM) for 6 or 48 hours, respectively: (a and b) MMP-3 (c and d) and MMP-13 (n 
= 8). SN and SC peptides (50 μM) were used as negative controls. NH2-FN-f (1 μM) was used as a positive control. (*) indicates significant comparisons 
in unstrained constructs for no treatment vs fragment; (ψ) indicates significant comparisons in unstrained constructs for fragment vs fragment + 1400 
W; + P < 0.05, ++ P < 0.01, +++ P < 0.001 indicates significant comparisons between treatment conditions as shown (n = 8).
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A key question is whether a threshold concentration of
fragmented matrix proteins exists, such that low levels
initiate early reparative events and switch to catabolic
insults at a later stage when the concentration increases
above a certain level. These points raise important ques-
tions which should be investigated further.
We next examined whether dynamic compression
could modulate the catabolic response induced by the
fragments in constructs cultured in a bioreactor. We
compared a continuous compression regime (C6 or C48)
with an intermittent protocol repeated once (10 minutes/
5 hr 50×1, 1.5 hr/4.5 hr×1) or eight times (10 minutes/5 hr
50×8, 1.5 hr/4.5 hr×8) during a 6 or 48 hour culture period.
Our findings indicate that continuous compression was
just as effective in downregulating fragment-induced NO
release as intermittent compression and the response
could be further downregulated with the iNOS inhibitor.
In contrast, modulation of MMPs and cytokines by
mechanical loading were dependent on the length and
type of compression regime applied. More specifically,
increasing the total number of compression cycles from
4800 to 172800 clearly had a greater inhibitory effect on
cytokine production and MMP-3 and 13 expression in
constructs stimulated with telopeptides. This is in con-
trast to constructs cultured with NH2-FN-f where the
shortest duration of intermittent compression was just as
effective in inhibiting cytokine production and MMP
expression when compared to longer cycles. Our findings
indicate that co-stimulation with dynamic compression
and the iNOS inhibitor was marginally better at down-
regulating catabolic activities for some of the fragment
conditions examined. The opposite effect was found for
anabolic activities, such that longer periods of compres-
sion resulted in a greater magnitude of stimulation of
sGAG content and expression of collagen type II and
f i b r o n e c t i n  e v e n  i n  t h e  p r e s e n c e  o f  f r a g m e n t s .  T h e
importance of these findings emphasises the nature of the
mechanical stimulus in controlling catabolic and anabolic
activities in chondrocytes. In a previous study utilising
the cell/agarose model, the number of cycles of compres-
sion, applied in a continuous or intermittent manner was
shown to be important in determining the nature of the
chondrocytes metabolic response [44]. For instance, fre-
quent bursts of intermittent compression for longer time
periods favoured proteoglycan synthesis whereas shorter
bursts of intermittent compression tended to favour cell
proliferation. A similar response was described by other
research groups which showed that the biochemical
response was dependent on the duration and type of
compression regime employed [45-48]. We could there-
Figure 7 Effect of NT and CT telopeptides and dynamic compression (15%, 1 Hz) on gene expression. Unstrained and strained constructs were 
cultured with either NT or CT peptide (both 50 μM) and/or 1400 W (1 mM) for 6 or 48 hours, respectively: (a and b) collagen type II and (c and d) 
fibronectin (n = 8). SN and SC peptides (50 μM) were used as negative controls. NH2-FN-f (1 μM) was used as a positive control. (*) indicates significant 
comparisons in unstrained constructs for no treatment vs fragment; (ψ) indicates significant comparisons in unstrained constructs for fragment vs 
fragment + 1400 W; + P < 0.05, ++ P < 0.01, +++ P < 0.001 indicates significant comparisons between treatment conditions as shown (n = 8).
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fore speculate that the intermittent loading regime used
in the present study mimics the physiological loading
environment of cartilage. In contrast, the continuous
compression regime could be interpreted as an excessive
or injurious response since these conditions favoured
rapid matrix turnover [49,50].
In healthy tissue, a small proportion of collagen and
fibronectin levels will maintain normal matrix turnover
and be released due to proteolytic digestion by MMPs
[49]. In the present study, some of the enhanced collagen
type II and fibronectin synthesis by dynamic compression
could be an initial response at repair which may later give
rise to catabolic activities involving increased synthesis of
MMPs and released fragments. There is good evidence
that mechanical loading conditions that mimic injury and
overloading which contribute to altered patterns of load
can accelerate mild damage with an early rebuilding
phase by increasing MMPs and metabolic activity [51-
55]. It is conceivable that the rebuilding phase may occur
indirectly through the effect of altered patterns of
mechanical loading by increasing the production of
growth factors (TGFβ1, IGF-1, bFGF), anti-inflammatory
cytokines (IL-4) or soluble mediators (Substance P, gluta-
mate) [56-60]. Furthermore, there is evidence that integ-
rins serve as receptors for both mechanical loading and
matrix fragments implicating overlapping pathways for
these signals [15,19,60,61]. Integrin-mediated mechan-
otransduction will contribute to chondroprotective
events resulting in the cells' attempt to stimulate anabolic
processes locally and assist in tissue remodelling [60].
This response will at least, in part, be dependent on the
type of mechanical loading regime, its duration and
whether loading was applied during the early or late stage
of the disease process. Thus, conditions such as obesity
or trauma that represent excessive or injurious loading
will increase catabolic activities and accelerate matrix
damage [48,62,63]. This disruption of matrix composi-
tion will contribute to abnormal biomechanics thereby
increasing NO production, reactive oxygen species and
chondrocyte death in vivo [64,65].
In summary, the present study demonstrates that
mechanical loading modulates the catabolic and anabolic
response of chondrocytes stimulated with collagen and
FN-fs. The catabolic response was dependent on the con-
centration and type of fragment such that for conditions
which represent cartilage degradation, collagen telopep-
tides were just as potent in increasing catabolic activities
as the FN-fs. Mechanical loading could reverse the cata-
bolic process induced by the fragments and enhance ana-
bolic activities. However, the response was dependent on
the length and type of compression regime applied. Fur-
thermore, co-stimulation by dynamic compression in the
presence of the iNOS inhibitor led to further time-depen-
dent increases in the expression of matrix proteins and
downregulation of cytokines and MMPs, implicating NO
dependent pathways. The ability of chondrocytes to
interact with matrix fragments and respond to biome-
chanical signals may be a key initiating event in the dis-
ease process. Further studies are needed to examine the
complexity of the sequence of signalling events which
interplay with biomechanical and matrix fragment signals
for early OA therapeutic intervention.
Conclusions
Telopeptides have dose-dependent catabolic activities
similar to FN-fs and increase the production of NO,
cytokines and MMPs. Catabolic activities were inhibited
by dynamic compression or by the presence of the iNOS
inhibitor, linking reparative activities by both types of
stimuli. Future investigations which examine the signal-
ling cascades of chondrocytes in response to matrix frag-
ments with mechanical influences may provide useful
information for early OA treatments.
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